A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease

By R. Casaburi, D. Mahler, P. Jones, A. Wanner, Pedro G San, R. Zuwallack, S. Menjoge, C. Serby, T. Witek. European Respiratory Journal, 2002

934 citations recorded by the source corpus.

Subfields: Physiology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/35aae72042583dface40ad06a2633436b8d861c9

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Physiology

1. P. Calverley
2. J. Wedzicha
3. T. Seemungal
4. D. Parums

In Pulmonary and Respiratory Medicine

1. J. Wedzicha
2. P. Calverley
3. T. Seemungal
4. R. Stockley
5. G. Hagan
6. Z. Ansari
7. D. Parums
8. P. Barnes

Citations in the corpus

• St. George's Respiratory Questionnaire: MCID (2005, background): “Effect of treatment on SGRQ score in three placebo controlled trials of long-acting bronchodilators: salmeterol (1), formoterol (19), and tiotropium (2).”
• The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. (2008, background): “On the basis of previous studies of long-acting bronchodilators (20, 21 ), we expected an exacerbation rate of 1.7 per patient per year in the tiotropium group and a 20% study withdrawal rate.”
• Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD (2004, result): “Improvements in spirometric parameters following treatment with tiotropium were consistent with previous studies (table 3) [11, 12 , 22].”
• COPD exacerbations: defining their cause and prevention (2007, neutral): “[74] [75] [76] [77] Thus lowering the exacerbation rate would be expected to decrease hospitalisations and have important health economic benefi ts.”